Company news
Rocket Pharmaceuticals, Inc. news in 2025
Rocket Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.
Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
November 24, 2025
Neurvati Neurosciences Appoints Carlos Martin as Chief Commercial Officer
November 13, 2025
Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
November 5, 2025
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
October 13, 2025
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635c4
October 13, 2025
Rocket Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
October 13, 2025
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 9, 2025
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
August 27, 2025
Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease
August 19, 2025
Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
August 6, 2025
Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs
July 23, 2025
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy
July 16, 2025
Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy
June 29, 2025
Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease
May 26, 2025
Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy
May 14, 2025
Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy
May 8, 2025
Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress
May 7, 2025
Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
April 2, 2025
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
February 26, 2025
Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
January 1, 2025
Decks in 2025
- Technical Presentation (May 2025)
Technical · 19 slides · May 15, 2025